MedElevator Войти в исследования
← Поиск публикаций

DOI 10.5114/aoms/190743

Медицинская библиотека · Archives of medical science : AMS · 2024

Cardiovascular and metabolic effects of ovarian suppression in combination with tamoxifen or an aromatase inhibitor as adjuvant therapy for early oestrogen receptor-positive breast cancer: a systematic review.

Gue Ying X, Lau Dorothy, Shantsila Alena, Lip Gregory Y H, Palmieri Carlo

СтатьяОбзорПеревод пока не подготовлен

Аннотация

INTRODUCTION

Adjuvant endocrine therapy is a key treatment in oestrogen receptor positive early breast cancer (BC). For premenopausal women, ovarian function suppression (OFS) in combination with either tamoxifen or aromatase inhibitor (AI) is utilised in high-risk cases. The resultant suppression of circulating oestradiol from OFS could have adverse cardiovascular and metabolic effects, subsequently increasing the risk of cardiovascular disease.

MATERIAL AND

METHODS

A systematic search of online databases was conducted to identify randomised control trials involving OFS which reported cardiovascular and metabolic adverse events. Pooled odds ratios (ORs) with 95% confidence intervals (CIs) were estimated using a random-effects model.

RESULTS

Four studies with a total of 7808 participants were included in the analysis. Tamoxifen alone carries a lower risk of hypertension compared with tamoxifen plus OFS (4.81% vs. 7.57%, OR = 0.67; 95% CI: 0.49-0.91; p = 0.01). The tamoxifen alone group showed a lower risk of hyperglycaemia compared to tamoxifen with OFS (0.10% vs. 0.86%, OR = 0.11; 95% CI: 0.02-0.85, p = 0.03).

CONCLUSIONS

Our study highlights the potential cardio-metabolic impact of endocrine therapy and OFS on premenopausal women with BC. It also highlights the pressing need for standardisation of routine collection and recording of cardiometabolic history and risk factors as part of baseline assessment and adverse event reporting to better understand the cardiometabolic impact these treatments have on our patients. Further studies, with particular focus on baseline and subsequent development of cardiovascular risk factors, are needed to explore the impact of these drugs on the cardiovascular health of young women with BC.

Для цитирования: Gue Ying X, Lau Dorothy, Shantsila Alena, Lip Gregory Y H, Palmieri Carlo. Cardiovascular and metabolic effects of ovarian suppression in combination with tamoxifen or an aromatase inhibitor as adjuvant therapy for early oestrogen receptor-positive breast cancer: a systematic review.. Archives of medical science : AMS. 2024. DOI: 10.5114/aoms/190743.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.